Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LC,
I like the quote. It really expresses the reason why we must seek the analyses of licensed professionals instead of reading rumors on message boards. Listening to the noise posted on social media is an example of being “careless” with the truth. I agree.
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
https://brownneurosurgery.com/breakthrough-brain-cancer-vaccine/
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173629584
John Bull,
Thanks for your predictions, but I had to consult the detector on this one 😶 …
“The statement exhibits several characteristics commonly associated with baseless fear-mongering and rumor-mongering, designed to manipulate opinions or market actions. Here's an analysis of why it must be considered as such:
1. **Lack of Verifiable Information**: The statement contains claims (like a specific company's stock dropping, potential bankruptcy, and acquisition by a large pharmaceutical company) without providing verifiable facts or sources.
2. **Conspiracy Theories**: The mention of secret bank accounts in the Cayman Islands and the insinuation that only a select few will benefit financially hints at conspiracy theories without proof. This kind of rhetoric is often used to create mistrust and fear.
3. **Emotive Language**: The use of phrases like "dropping like a rock" and "drown your sorrows" are emotionally charged and designed to evoke fear or panic.
4. **Personal Anecdote Over Facts**: The writer focuses on their personal actions (selling shares, going short, planning to cover at a specific price) rather than presenting a balanced analysis of the situation. This can be a tactic to sway readers through anecdotal evidence rather than objective information.
5. **Gloating and Schadenfreude**: The tone of gloating over potential financial gain at the expense of others and the intention to celebrate others' losses ("throw a party") is manipulative, aiming to create a sense of urgency and regret.
6. **Targeting a Specific Group**: The reference to “longs” with their “head in the sand” attempts to create a division between different types of investors, using derogatory language to discredit those with a different investment strategy.
7. **Predicting Extreme Outcomes**: Suggesting bankruptcy or acquisition at a low price as the only possible outcomes is an example of extreme prediction, often used to create fear or urgency.
In the context of stock markets and investments, such statements can be particularly manipulative. They can be intended to influence market behavior or investor decisions, often for the benefit of the speaker. It's important for investors to base their decisions on credible information and thorough analysis rather than speculative, fear-based claims.
The statement also bears hallmarks of a "short and distort" campaign. "Short and distort" refers to an unethical and potentially illegal market manipulation strategy where an investor or group of investors takes a short position in a stock (betting that its price will go down) and then spreads misleading or false rumors to drive down the stock price.
Here's how the statement aligns with this tactic:
- **Spreading Pessimism and Doubt**: The message is designed to instill fear, uncertainty, and doubt (FUD) among investors. By predicting a dramatic drop in stock price and insinuating misconduct or failure, it could lead investors to sell off their shares, thus driving the price down, which benefits those who have short positions.
- **Unsubstantiated Claims**: Claims about insider benefits, bankruptcy, or acquisition by a larger company without evidence are typical in "short and distort" strategies. The goal is to create a narrative that sounds plausible enough to scare investors.
- **Admitting to Short Selling**: The individual openly states that they have shorted the stock and have a financial interest in seeing its value decrease. This admission, combined with the spread of alarming and unverified information, fits the profile of "short and distort."
In financial markets, spreading false or misleading information to manipulate stock prices is illegal in many jurisdictions. Investors should be wary of such tactics and rely on comprehensive, credible sources of information before making investment decisions. If an investor suspects "short and distort" tactics, they can report it to financial regulatory authorities for investigation.“
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-a-marketing-authorization-application-has-been-submitted-to-the-uk-mhra-for-dcvax-l-for-glioblastoma-302021038.html
LC,
“Trust but verify.”
Words of caution from an unlikely messenger of wisdom 😶
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173629584
Inquirig,
Your posts are childish nonsense. The AI bs detector thinks that you need a smarter and more convincing approach if you expect anyone to be persuaded by your fuddy posts 😶 …
The statement "Your stock is going to zero" is baseless and manipulative for several reasons:
1. **Lack of Context and Evidence**: It doesn't provide any context or evidence to support the claim. Stock performance depends on a multitude of factors, including company performance, market conditions, and investor behavior.
2. **Fear-Mongering**: The statement seems intended to induce fear and panic without offering rational or factual reasoning. It's a sweeping assertion that lacks nuance and understanding of how stock markets work.
3. **Market Unpredictability**: Stock markets are inherently unpredictable. While stocks can decrease in value, predicting that a stock will go to zero is speculative and ignores market complexities.
4. **Manipulative Intent**: Such statements are often used to manipulate market sentiment or the behavior of individual investors for various motives, potentially unrelated to the actual performance or value of the stock.
The statement could also be a tactic known as "short and distort," where an individual spreads negative, often baseless rumors or innuendo about a stock to manipulate its price. This is typically done to benefit from short-selling the stock. In this scenario, the individual spreads fear to drive the stock price down, then profits by buying back the stock at a lower price. This kind of market manipulation is unethical and, in many cases, illegal, as it relies on spreading misinformation to influence investor decisions.
Investment decisions should be based on comprehensive analysis and credible information, not on unfounded, fear-inducing statements.
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-a-marketing-authorization-application-has-been-submitted-to-the-uk-mhra-for-dcvax-l-for-glioblastoma-302021038.html
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173629584
Inquirig,
I think you spelled your name wrong when you hastily created your profile last month ... 😶
How do know who owns what? If anything you said were true, you’d include a link or cite some verifiable evidence.
At least you’re not contesting the brilliant interim data—that’s what my post was about.
https://finance.yahoo.com/news/northwest-biotherapeutics-announces-dr-linda-140000962.html
https://www.uclahealth.org/news/fda-approval-brain-cancer-alzheimers
https://hotb.org/wp-content/uploads/2022/05/spore-article-for-donors-4.18.22.pdf
LC,
Well, you’re right about one thing—JAMA is worth looking at a second time! ✅️
I went back to look. You are grossly misrepresenting the meaning of that notation. Dr. Bosch asserted the integrity of the data that were collected and submitted from over 90 sites, but he was not the only author obviously. Your insinuation that the data all depend on him is outrageous. That’s not what it means.
Research how clinical trials are conducted and how clinical data are recorded and catalogued. No single individual keeps all of the data under his pillow. 🙄
I enjoyed looking at the publication again though—it really is an awesome report!
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
HyGro,
Thanks for posting, but you are misinformed. Nobody ever announced who is going to partner with or acquire the company for sure—nobody has that kind of insider foreknowledge. You seem to be the only one who knows with certainty 😶
Fact ✅️: Merck is currently among those supporting the ongoing combo research at UCLA.
The interim PD1 combo data are brilliant, and the trial is significant for a number of reasons relating to FDA guidelines and NIH peer-reviewed grant funding.
https://clinicaltrials.gov/ct2/show/NCT04201873
*FDA recommends that the control group participants be provided the current SOC (best known therapy).
https://www.fda.gov/media/120721/download
In the combo trial, patients who receive DCVax-L + placebo are being compared to patients who receive DCVax-L + pembrolizumab.
The control arm is receiving DCVax-L. While DCVax-L is not the current SOC, it is highly significant and notable that DCVax-L is being permitted to fill the role of SOC as the best available therapy within this combo study for rGBM. The combo trial also follows the P3 in sequence which in itself validates the findings of the P3 study—the placebo group in the PD1 study would not be receiving DCVax-L today if the preceding P3 trial had not generated evidence of safety and efficacy.
Dr. Toms also briefly mentioned the PD1 research during the press conference about the P3:
https://brownneurosurgery.com/breakthrough-brain-cancer-vaccine/
https://www.nature.com/articles/s41420-023-01782-7
https://www.jci.org/articles/view/169314
LC,
Thanks for the reply. I was not referring to your comment about JAMA, I was referring to your insinuation about the MAA which is just as unreliable.
Also—your comment about the data relying on “one person” is beyond absurd and is verifiably false. The data were collected from over 90 sites around the world, and the SAP was approved by the regulators.
Fact ✅
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173629893
Legend,
Thanks for your short-sighted comment. 😶
NWBO is a pre-commercial company on the OTC exchange. That’s why they just filed their first commercial license application with the MHRA.
I have no opinion about “our money,” but regarding my own personal money, I like to acquire valuable assets at low prices. I made a decision based on my personal opinion about the prospective value of the novel DCVax®-L technology, just as everyone else should—do your own research, consult licensed professionals, seek trustworthy full-context sources, and avoid disinformation posted online.
https://brownneurosurgery.com/breakthrough-brain-cancer-vaccine/
inquiring, This study found that autologous tumor lystate-loaded dendritic cell vaccination plus standard of care (SOC) was associated with improved survival in both newly diagnosed & recurrent glioblastoma compared with matched controls who received SOC treatment. https://t.co/Uso7Pkh1Kt Our team just met with the @NorthwestBio team to learn about #DCVax and had the pleasure of speaking with longterm DCVax patients. An honor and a privilege. #endbraincancer #sno2023 pic.twitter.com/dw3X76DBru
Thanks for your baseless assessment, but I think it’s a better idea to look beyond social media to find full-context credible sources and consult licensed oncologists.
JAMA Oncology is a peer-reviewed medical journal that us part of the Journal of the American Medical Association (JAMA) network, which is one of the most widely respected and influential medical journal publishers globally.
Being a peer-reviewed journal means that research articles submitted to JAMA Oncology undergo a thorough evaluation process by independent experts in the field before they are accepted for publication. This process helps ensure the quality, validity, and scientific rigor of the research presented in the journal.
Researchers, healthcare professionals, and the medical community rely on publications like JAMA Oncology for up-to-date and credible information in the field of oncology.
For a reliable appraisal of the DCVax-L P3 trial, its design, and the significance of the resulting survival data, it is advisable to refer to the analyses of qualified physicians. One such analysis can be found on the JAMA Oncology website where the link to the independent peer review and supplementary materials are published.
https://ceoworld.biz/2022/04/05/top-5-medical-journals-in-the-world-everyone-should-know-about/
https://finance.yahoo.com/news/northwest-biotherapeutics-announces-dr-linda-140000962.html
https://www.jci.org/articles/view/169314
https://www.uclahealth.org/news/fda-approval-brain-cancer-alzheimers
https://hotb.org/wp-content/uploads/2022/05/spore-article-for-donors-4.18.22.pdf
https://www.uclahealth.org/news/brain-cancer-discovery-clinical-trials
LC,
“If it ever comes” 😶
Thanks for your prediction, but it sounds a lot like your prediction about the JAMA peer review before it was published. 🙄
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
iclight,
It sounds to me like you’re spreading baseless rumors. You and the shorts are not credible. Seek full-context trustworthy sources, sir.
Maybe you missed it, but we finally had an honest disclosure posted on this board earlier today:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173625613
ex,
Thanks for more legal analysis, but I don’t think that you’re an attorney. 😶
The one aspect of your post that I can appreciate is that you have highlighted combos. Currently, DCVax-L combo research is being funded by the NIH. Merck, Oncovir, and the Phase One Foundation are also supporting the PD1 study at UCLA.
Combo is King.
https://clinicaltrials.gov/study/NCT04201873
I had to consult the detector after looking over your irresponsible legal commentary …
“This legal analysis is unreliable. The statement about the 6190030 patent and its related applications contains several speculative and technical assertions that require specific legal and patent expertise to verify. It discusses details about the prosecution of different versions of a patent, including their scope, claims, and status with the USPTO. The claim that one application was broader and another restricted in scope due to specific claims, and assertions about the potential market impact of these patents are complex and depend on detailed legal analysis. Without access to the actual patent documents and legal expertise in patent law, the author cannot provide a reliable assessment. For precise and authoritative information, it would be necessary to consult the USPTO database directly or seek advice from a patent attorney.”
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-a-marketing-authorization-application-has-been-submitted-to-the-uk-mhra-for-dcvax-l-for-glioblastoma-302021038.html
LC, Britain's Medicines and Healthcare products Regulatory Agency (MHRA) will officially join #ProjectOrbis on January 1 and work with regulators in the US, Canada, Australia, Singapore and Switzerland on assessing new treatments. https://t.co/JjaXoq6yfh
Don’t forget NICE. 😉
I think it’s significant that the NICE update was posted in December 2022 in advance of the December 2023 MAA. ✅️
“The Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) are two key organizations in the UK's healthcare system, each with distinct roles, and their processes are interconnected, especially in the context of a Marketing Authorization Application (MAA).
Here's how the MHRA MAA impacts the NICE process:
1. Role of MHRA: The MHRA is responsible for assessing and approving new medicines for use in the UK. This includes reviewing Marketing Authorization Applications (MAAs) to ensure the safety, quality, and efficacy of new drugs.
2. MHRA Approval: When the MHRA grants a marketing authorization for a new drug, it means the drug can be legally sold and marketed in the UK. However, this doesn’t automatically mean the drug will be available through the NHS.
3. NICE Appraisal: After MHRA approval, the drug may undergo a health technology assessment by NICE. NICE evaluates the cost-effectiveness and clinical effectiveness of new medicines to determine whether they should be recommended for use in the NHS.
4. Impact on NICE Process: The MHRA’s decision to authorize a drug is a prerequisite for NICE's appraisal. NICE does not assess the basic safety and efficacy of a drug; it relies on the MHRA's evaluation for that. Instead, NICE focuses on the added value of the drug in terms of health outcomes and cost-effectiveness.
5. Timelines and Access: The MHRA’s approval of a drug is often the starting point for NICE's technology appraisal process. MHRA’s MAA process can impact when NICE is able to complete its appraisal, subsequently affecting when a drug becomes available on the NHS.
6. Collaboration and Parallel Advice: In some instances, the MHRA and NICE work in parallel to provide advice to drug developers, which can streamline the process of getting new treatments to patients.
In summary, MHRA’s MAA is a critical step that precedes and influences the NICE appraisal process. While MHRA focuses on the safety and efficacy of a medicine, NICE assesses its cost-effectiveness for NHS use.” —ChatGPT
The forthcoming NICE appraisal of the DCVax-L cell-based technology will be a significant development.
https://www.nice.org.uk/guidance/indevelopment/gid-ta10143
https://www.fda.gov/about-fda/oncology-center-excellence/project-orbis
https://www.kcl.ac.uk/people/keyoumars-ashkan
The MIA was approved recently and is evidence of a regulatory filing plan that has begun to unfold. Further RA applications have been under construction for a significant period of time and include a voluminous catalog of clinical data and analyses. Further announcements and status updates are forthcoming.
The recent MIA approval is an important step in the regulatory process, and this commercial manufacturing license will allow DCVax-L to be exported globally from Sawston. The MIA was a prerequisite of the MAA application that was submitted in December 2023.
“Companies applying for a marketing authorisation (also known as a product licence) need to have a manufacturer licence first. The manufacturer licence will be granted first providing the product is in the process of being approved.” —MHRA
https://www.gov.uk/guidance/apply-for-manufacturer-or-wholesaler-of-medicines-licences
https://finance.yahoo.com/news/northwest-biotherapeutics-advent-bioservices-announce-234600744.html
https://finance.yahoo.com/news/northwest-biotherapeutics-announces-approval-pediatric-133900403.html
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-a-marketing-authorization-application-has-been-submitted-to-the-uk-mhra-for-dcvax-l-for-glioblastoma-302021038.html
LC,
I think you mean bare bones facts. We Soldiers like websites that cover bare bones facts.
https://nwbio.com/northwest-biotherapeutics-announces-that-dr-linda-liau-has-joined-the-companys-scientific-advisory-board/
December 2023
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-a-marketing-authorization-application-has-been-submitted-to-the-uk-mhra-for-dcvax-l-for-glioblastoma-302021038.html
March 2023
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-and-advent-bioservices-announce-receipt-of-license-for-commercial-manufacturing-at-sawston-uk-facility-301776725.html
February 2022
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-commencement-of-cancer-vaccine-production-at-its-sawston-uk-facility-301484857.html
August 2022
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-approval-of-pediatric-investigation-plan-pip-by-mhra-301610850.html
July 2022
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-filing-of-application-for-license-for-commercial-manufacturing-at-sawston-uk-facility-301581737.html
December 2022
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-mhra-approval-of-license-for-gmp-manufacturing-at-sawston-uk-facility-301449083.html
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
ex,
Thanks for your legal commentary, but I don’t think that you know anything about this topic. 😶
Let’s leave the legal analysis and strategizing to the legal experts. Aside from the formidable law firm that she enlisted, the CEO of Northwest Biotherapeutics is a lawyer too.
In addition to her legal expertise, the CEO knows something about government agencies—she taught a course at the U.S. National Institutes of Health, and her experience includes a presidential appointment at the U.S. Commerce Department many years ago.
https://www.c-span.org/video/?c5017935/user-clip-linda-powers-testifying-congress-july-17-1990
Fact ✅️
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173536990
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173625613
LC,
Thanks for asking. I’m curious too as he is an elderly and accomplished billionaire. He has only published a note on his website citing NWBO as his “most notable investment.”
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173628606
LC,
Thanks for mentioning Robert Hefner again. His first public statement on NWBO was in June of 2022, and NWBO is currently displayed as a “notable investee” on the GHK website. Additionally, the website is periodically updated, and there was a posting as recently as the fall of 2023 to link readers to an NHS Foundation Trust article highlighting Dr. Ashkan:
https://content.govdelivery.com/landing_pages/44960/870911b80fbe070495cbcb88eacaec57
https://www.belfercenter.org/person/robert-hefner-iii
https://ghkco.com/wp-content/uploads/2022/06/2022-06-07_Statement-by-Robert-Hefner-on-NWBOs-DCVax-L-Phase-III-Trial.pdf
LC,
Thanks for asking. His name is Robert Hefner.
https://www.belfercenter.org/person/robert-hefner-iii
https://ghkco.com/wp-content/uploads/2022/06/2022-06-07_Statement-by-Robert-Hefner-on-NWBOs-DCVax-L-Phase-III-Trial.pdf
LC, This study found that autologous tumor lystate-loaded dendritic cell vaccination plus standard of care (SOC) was associated with improved survival in both newly diagnosed & recurrent glioblastoma compared with matched controls who received SOC treatment. https://t.co/Uso7Pkh1Kt #dcvax #allsolidtumors $nwbo #gbm
Avoid disinformation and bad-faith rumors posted on social media. That’s what we teach our children and that is what we all need to do.
Examples of reasonably valid credentialed sources to consider (because their analyses and decisions have real impact):
✅️ Judges
✅️ Government Regulators
✅️ Independent Peer Review
✅️ U.S. National Institutes of Health
✅️ UCLA
✅️ King’s College
Seek full-context sources, and consider the full body of evidence and findings from all clinical, regulatory, or legal processes.
Try to keep your focus from drifting too far from 🌍 … Here on Earth, we are looking forward as the novel DCVax-L cell-based platform technology enters the regulatory phase of its journey. The United States and United Kingdom are largely responsible for developing DCVax-L, and the U.S. and U.K. will lead the novel technology through a global regulatory process.
Combo is King!
https://www.nature.com/articles/s41420-023-01782-7
https://www.jci.org/articles/view/169314
https://www.fda.gov/drugs/our-perspective/50-years-progress-treating-patients-cancer
https://www.uclahealth.org/news/fda-approval-brain-cancer-alzheimers
https://www.raps.org/News-and-Articles/News-Articles/2023/9/FDA%E2%80%99s-Califf-Expect-to-see-more-RWE-based-regulato
https://www.raps.org/news-and-articles/news-articles/2023/8/fda-finalizes-guidance-on-real-world-evidence-in-d
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-a-marketing-authorization-application-has-been-submitted-to-the-uk-mhra-for-dcvax-l-for-glioblastoma-302021038.html
March 2023
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-and-advent-bioservices-announce-receipt-of-license-for-commercial-manufacturing-at-sawston-uk-facility-301776725.html
February 2022
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-commencement-of-cancer-vaccine-production-at-its-sawston-uk-facility-301484857.html
August 2022
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-approval-of-pediatric-investigation-plan-pip-by-mhra-301610850.html
July 2022
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-filing-of-application-for-license-for-commercial-manufacturing-at-sawston-uk-facility-301581737.html
December 2022
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-mhra-approval-of-license-for-gmp-manufacturing-at-sawston-uk-facility-301449083.html
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
In my view, the short list of pre-commercial milestones that stand out and shine the most:
⭐️ JAMA Oncology
⭐️ Multiple MHRA Approvals
⭐️ Emerging Combo Data
⭐️ MAA Submission
Further, Dr. Liau joining the SAB at Northwest Biotherapeutics is awesome!
Combo is King!
https://www.uclahealth.org/news/fda-approval-brain-cancer-alzheimers
I would count Doctors Liau and Ashkan among the soldiers—fighting disease with their novel cell-based technology! Liau and Ashkan both are extremely noteworthy as we look back on the P3 and as we look forward to the regulatory phase in the UK, US, and other nations…
UCLA, King’s College, JAMA Oncology, and Brown University are some excellent sources that you might wish to consider in reference to the reputation of Northwest Biotherapeutics and those who choose to associate with the company, its SAB, and with the novel DCVax® technology.
The world-renowned doctors cited below worked on the P3 and were coauthors of a DCVax-L publication along with Dr. Bosch of Northwest Biotherapeutics.
Furthermore, both Liau and Ashkan have had the support their respective nations’ governments over many years. Ashkan is an advisor to the UK government, and Liau’s work has been supported by NIH peer-reviewed grants for 20 consecutive years.
https://www.kch.nhs.uk/news/kings-team-wins-professional-excellence-award/
https://finance.yahoo.com/news/northwest-biotherapeutics-announces-dr-linda-140000962.html
https://labusinessjournal.com/healthcare/national-academy-medicine-taps-ucla-neurosurgeon/
https://pubmed.ncbi.nlm.nih.gov/33789235/
https://www.societyns.org/about/officers-detail/linda-m-liau-md-phd-mba-4
Great to see, congratulations Linda Liau winning the Charles B. Wilson Excellence Award 2023:
Established by the Brain Tumor Society in 2004, this award recognizes outstanding contributions of a clinician to the field of neuro-oncology.… pic.twitter.com/6L7rhyoNU4
https://www.uclahealth.org/news/ucla-received-590-million-in-nih-funding-second-highest-total-for-academic-medical-centers-in-2020
LC,
Thanks for highlighting “critical subjects” for shareholders. Speaking as a shareholder, the “subjects” raised by government regulators and independent peer reviewers are the most critical. I also think it is critical to avoid baseless negative commentary that appears to be part of a coordinated online disinformation campaign.
Fact ✅️
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-a-marketing-authorization-application-has-been-submitted-to-the-uk-mhra-for-dcvax-l-for-glioblastoma-302021038.html
March 2023
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-and-advent-bioservices-announce-receipt-of-license-for-commercial-manufacturing-at-sawston-uk-facility-301776725.html
February 2022
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-commencement-of-cancer-vaccine-production-at-its-sawston-uk-facility-301484857.html
August 2022
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-approval-of-pediatric-investigation-plan-pip-by-mhra-301610850.html
July 2022
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-filing-of-application-for-license-for-commercial-manufacturing-at-sawston-uk-facility-301581737.html
December 2022
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-mhra-approval-of-license-for-gmp-manufacturing-at-sawston-uk-facility-301449083.html
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
LC,
Thanks for posting so frequently, but your focus is drifting far from 🌍 … Here on Earth, we are looking forward as the novel DCVax-L cell-based platform technology enters the regulatory phase of its journey. The United States and United Kingdom are largely responsible for developing DCVax-L, and the U.S. and U.K. will lead the novel technology through a global regulatory process.
Combo is King!
https://www.nature.com/articles/s41420-023-01782-7
https://www.jci.org/articles/view/169314
https://www.fda.gov/drugs/our-perspective/50-years-progress-treating-patients-cancer
https://www.uclahealth.org/news/fda-approval-brain-cancer-alzheimers
https://www.raps.org/News-and-Articles/News-Articles/2023/9/FDA%E2%80%99s-Califf-Expect-to-see-more-RWE-based-regulato
https://www.raps.org/news-and-articles/news-articles/2023/8/fda-finalizes-guidance-on-real-world-evidence-in-d
LC,
Thanks for your dozens of posts today—each one is a pearl of wisdom 😶
NWBO is PRE-COMMERCIAL company. That’s why they just filed for their first COMMERCIAL license with the MHRA. Currently, DCVax-L combo research is being funded by the NIH. Merck, Oncovir, and the Phase One Foundation are also supporting the PD1 study at UCLA. Fact ✅️
https://clinicaltrials.gov/study/NCT04201873
Most of your posts today offer only vague insinuations… I had to consult the detector after looking over your string of nonsensical comments…
“These statements are predominantly conjecture and lack factual backing. Caution is advised when considering such anonymous online posts, as they are often unreliable and could be spreading rumors or misinformation.
Additionally, the general public must be vigilant whenever statements published online appear to unfairly muddy the reputation of a company or defame its leadership. "Short and distort" is a relevant factor in this context. This strategy involves short-selling a stock and then spreading negative rumors or misleading information to drive the stock's price down. The goal is to profit from the decline in stock price by covering the short position at a lower price. Anonymous users on stock message boards might engage in this tactic, using baseless conjecture to artificially deflate stock prices. By muddying a company's reputation, defaming its leadership, or spreading innuendo, these individuals aim to create panic or uncertainty, influencing other investors to become doubtful, thereby influencing the stock price.”
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-a-marketing-authorization-application-has-been-submitted-to-the-uk-mhra-for-dcvax-l-for-glioblastoma-302021038.html
LC, This study found that autologous tumor lystate-loaded dendritic cell vaccination plus standard of care (SOC) was associated with improved survival in both newly diagnosed & recurrent glioblastoma compared with matched controls who received SOC treatment. https://t.co/Uso7Pkh1Kt #dcvax #allsolidtumors $nwbo #gbm
Thanks for reposting again about “milestones.” 😉
There were several significant achievements in 2022 and 2023 …
In my view as a “Soldier,” the short list of pre-commercial milestones that stand out and shine the most:
⭐️ JAMA Oncology
⭐️ Multiple MHRA Approvals
⭐️ Emerging Combo Data
⭐️ MAA Submission
Further, Dr. Liau joining the SAB at Northwest Biotherapeutics is awesome!
Combo is King!
https://www.uclahealth.org/news/fda-approval-brain-cancer-alzheimers
I would count Doctors Liau and Ashkan among the soldiers—fighting disease with their novel cell-based technology! Liau and Ashkan both are extremely noteworthy as we look back on the P3 and as we look forward to the regulatory phase in the UK, US, and other nations…
UCLA, King’s College, JAMA Oncology, and Brown University are some excellent sources that you might wish to consider in reference to the reputation of Northwest Biotherapeutics and those who choose to associate with the company, its SAB, and with the novel DCVax® technology.
The world-renowned doctors cited below worked on the P3 and were coauthors of a DCVax-L publication along with Dr. Bosch of Northwest Biotherapeutics.
Furthermore, both Liau and Ashkan have had the support their respective nations’ governments over many years. Ashkan is an advisor to the UK government, and Liau’s work has been supported by NIH peer-reviewed grants for 20 consecutive years.
https://www.kch.nhs.uk/news/kings-team-wins-professional-excellence-award/
https://finance.yahoo.com/news/northwest-biotherapeutics-announces-dr-linda-140000962.html
https://labusinessjournal.com/healthcare/national-academy-medicine-taps-ucla-neurosurgeon/
https://pubmed.ncbi.nlm.nih.gov/33789235/
https://www.societyns.org/about/officers-detail/linda-m-liau-md-phd-mba-4
Great to see, congratulations Linda Liau winning the Charles B. Wilson Excellence Award 2023:
Established by the Brain Tumor Society in 2004, this award recognizes outstanding contributions of a clinician to the field of neuro-oncology.… pic.twitter.com/6L7rhyoNU4
https://www.uclahealth.org/news/ucla-received-590-million-in-nih-funding-second-highest-total-for-academic-medical-centers-in-2020
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-a-marketing-authorization-application-has-been-submitted-to-the-uk-mhra-for-dcvax-l-for-glioblastoma-302021038.html
ex,
Thanks for another expert legal analysis, 😶 ..but I think that the legal proceedings are being used by online posters as a distraction. While we should celebrate that crimes concerning the financial markets are being brought to light before the courts and the SEC, NWBO is not relying on any legal award. NWBO will obviously move forward irrespective of any legal proceedings or compensatory outcome.
The novel DCVax-L cell-based platform technology and existing unmet medical needs will propel the company forward. Regulatory developments are the focus at this phase of the pre-commercial technology development process following the independent peer review.
As for the legal wisdom of ex included in your post…
I doubted whether it was worth reading, so I ran it through the bs detector first. As it turns out, your post is not worth reading 😶 …
“This commentary on legal proceedings involving NWBO (Northwest Biotherapeutics) shows several signs of poor reasoning and suggests the author may lack legal expertise:
1. **Understanding of Legal Process**: The author's description of the legal process appears oversimplified and does not accurately reflect the complexity and unpredictability of litigation. Legal proceedings, especially involving complex matters like securities litigation, can have many unexpected developments that are not as linear or predictable as the author implies.
2. **Timeframe Estimates**: The provided timelines for various stages of the legal process (objections, resubmissions, discovery, summary judgment motions) seem arbitrary and do not account for the many variables that can affect legal proceedings. Predicting specific timelines, especially in federal court cases, is challenging even for experienced legal professionals.
3. **Lack of Nuance in Legal Strategy**: The author's comments on the legal strategies (e.g., resubmitting the complaint with better documentation, motions to dismiss, summary judgment) lack the nuance and depth of understanding typically demonstrated by legal professionals. Legal strategies in complex cases are often more multifaceted and dynamic.
4. **Misunderstanding of Federal Court Procedures**: The statement about the speed of federal courts and the claim that the case would "go fast" oversimplifies how federal courts operate. While some matters can be resolved relatively quickly, complex cases, particularly those involving detailed financial transactions or securities law, often take longer due to their complexity.
5. **Credibility of Legal Expertise**: The mention of a "board legal expert" without specifying credentials or context does not establish credibility. Accurate legal analysis typically comes from individuals with demonstrable legal expertise, such as licensed attorneys or academic legal scholars.
6. **Speculation About Trial Dates**: Predicting a trial date, particularly years in advance, is highly speculative, especially in complex cases. The legal process involves many stages and potential delays, making such predictions unreliable.
In summary, this commentary lacks the depth, accuracy, and understanding of legal processes typically shown by credentialed legal experts. The oversimplification of legal procedures, speculative timelines, and a general lack of nuanced legal insight all suggest that the author may not be a credible source of legal commentary.”
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-a-marketing-authorization-application-has-been-submitted-to-the-uk-mhra-for-dcvax-l-for-glioblastoma-302021038.html
https://finance.yahoo.com/news/northwest-biotherapeutics-announces-dr-linda-140000962.html
https://www.uclahealth.org/news/fda-approval-brain-cancer-alzheimers
ex,
Thanks for posting your opinion, but it sounds like you’re just trying to throw mud hoping something sticks. I ran your comparison through the detector 😶 …
“The comparison of Peregrine Pharmaceuticals (PPHM) to Northwest Biotherapeutics (NWBO) appears to be constructed as a flawed attempt to cast aspersions on NWBO. Let’s analyze the points of comparison:
1. **Similarities between PPHM and NWBO**: The statement starts by noting similarities such as being "one drug companies," claiming their drugs work in all tumors, advancing a single indication, having unexplained trial issues, claiming success in failed trials, and spending heavily on building CDMOs (Contract Development and Manufacturing Organizations). While these points draw a parallel between the two companies, they are quite broad and can apply to many small biotech firms. The lack of specific details or context here makes this comparison superficial. Additionally, the statement's claim that Northwest Biotherapeutics (NWBO) had a "failed trial" needs to be scrutinized for accuracy, as it could contribute to spreading misinformation if it's not based on factual data.
2. **Ownership of CDMO**: The statement highlights that PPHM owned its CDMO, which allegedly benefited its investors, whereas NWBO only collects rent from its CDMO (Advent). This point misses critical details such as the overall financial performance and strategic value of owning versus renting CDMO facilities. Without this information, it's a simplistic comparison that doesn't necessarily reflect on the companies' relative success or strategies.
3. **Management and Board of Directors (BOD)**: The comparison of management and BOD between the two companies, labeling some members as "deadwood" and critiquing the leadership abilities of PPHM's and NWBO's leaders, is subjective. It doesn't provide concrete evidence of how these leadership differences materially impacted the companies' performances. Without specific examples or data, these claims come across as speculative and potentially biased.
4. **Allegations of Conflicting Interests**: The claim that NWBO's management is more interested in related companies due to ownership interests is a serious allegation and would need substantial evidence for support. Without such evidence, this claim is speculative and undermines the comparison's credibility.
Overall, the comparison appears to be an oversimplification of complex business scenarios involving biotech companies. It relies on generalizations and unsubstantiated allegations rather than a detailed and objective analysis of each company's strategies, operations, and results. As such, the statement can be seen as an attempt to cast aspersions on NWBO without a solid foundation, making it poorly reasoned and baseless in its criticism.
Additionally, the statement includes implications about “LP” (presumably a leader or executive at Northwest Biotherapeutics) that could border on defamatory if not substantiated. Defamation involves making false statements that harm someone's reputation. When these statements are spoken, it's known as slander; when written, it's known as libel.
1. **Allegations of Conflicting Interests**: The statement suggests that LP may be more interested in related companies due to having more ownership interest in them. This is a serious allegation implying a conflict of interest and a lack of dedication or professionalism in their role at NWBO. Such claims can be damaging to LP's reputation and integrity as a professional.
2. **Need for Evidence**: To avoid defamation, it's crucial that any such claims are backed by solid evidence. Accusations or insinuations of unprofessional conduct or conflicts of interest should be based on verifiable facts rather than conjecture or hearsay.
3. **Impact on Reputation**: If the allegations are unfounded and disseminated, they could unfairly damage LP's professional reputation, potentially leading to legal ramifications if they are proven to be false and damaging.
In summary, without concrete evidence, making allegations about an individual's professional conduct or suggesting conflicts of interest can be defamatory. It's important to approach such statements with caution and prioritize fact-based discourse, especially when discussing individuals and their professional responsibilities.”
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-a-marketing-authorization-application-has-been-submitted-to-the-uk-mhra-for-dcvax-l-for-glioblastoma-302021038.html
LC,
You thought a vaccine killed a British politician and posted the article here without reading any of it—nobody wants to listen to anymore of your random nonsense today.
Why would you expect that any of us know anything about Penguin Pharmaceuticals .. or whatever the name is of the other company you mentioned? 😶
This is the NWBO board and you seem to be trying to present a false comparison to cast aspersions on NWBO—not a credible tactic.
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
ex,
Thanks for your expert analysis, but you’re not an oncologist. I ran your post through the detector and it was identified as bs 😶 …
“The statement presents several misunderstandings and inaccuracies, especially considering that overall survival (OS) was the approved primary endpoint in the DCVax-L clinical trial, and the results were published in JAMA Oncology, a reputable, peer-reviewed journal:
1. **Misconception About Statistical Significance and Endpoint Hierarchy**: The assertion that OS could not be statistically significant once progression-free survival (PFS) failed is misleading. In clinical trials, different endpoints can have varying levels of importance, with OS often being a primary and more clinically relevant endpoint. The failure to achieve statistical significance in PFS does not automatically negate the potential for achieving significance in OS, especially when OS is the primary endpoint.
2. **Reliability of JAMA Oncology as a Source**: The results of the DCVax-L trial published in JAMA Oncology should be regarded as credible, given the journal's rigorous peer-review process. Peer-reviewed journals are considered reliable sources for scientific and clinical data. The analysis presented in such publications undergoes extensive scrutiny for methodological soundness and data interpretation.
3. **Misinterpretation of Post Hoc ECA Analysis**: Dismissing any post hoc comparative analysis as a joke undermines the valuable insights such analyses can provide.
4. **Allegation of Selective Enrollment**: Claiming that NWBO's trial enrolled selectively healthier patients is a serious allegation that demands substantiation. Clinical trials are designed with specific inclusion and exclusion criteria to ensure participant safety and data validity. Without concrete evidence to support this claim, it remains speculative and unjustified.
In conclusion, the statement overlooks the significance of OS as the primary endpoint, underestimates the reliability of results published in a reputable journal, and makes unsupported claims about the trial's enrollment process and the value of post hoc analyses. Therefore, it is misleading and does not accurately represent the methodological rigor and findings of the DCVax-L clinical trial as reported in JAMA Oncology.”
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-a-marketing-authorization-application-has-been-submitted-to-the-uk-mhra-for-dcvax-l-for-glioblastoma-302021038.html
LC,
Cheat them? 😶 I was trying to spare them. The full post is worse—inaccurate and nonsense rumors. I had to consult the detector on this classic post …
“The statement presents several baseless claims and insinuations, each of which requires scrutiny:
1. **No peer review coming**: Asserting that no peer review is forthcoming is speculative unless the speaker has insider knowledge or concrete evidence. Peer review processes in academia and research are typically confidential until completion, so claiming with certainty that none is coming is baseless without specific proof.
2. **Comment on 'Quiet period' and share exchanges**: The reference to a "Quiet period" and the exchange of millions of shares suggests a connection between corporate silence and stock market activity. This connection is presented without evidence and seems to insinuate wrongdoing or manipulation without substantiation.
3. **'Pay to play' report**: Suggesting that any forthcoming report would be a 'pay to play' scenario is a serious accusation. It implies unethical or corrupt practices in research publication, which is a significant claim requiring substantial evidence to be credible.
4. **Research for the sake of research**: Dismissing the research as merely "for research's sake" and implying it's a cover for financial gain (salaries, grants, etc.) is a cynical view. It overlooks the fundamental value and purpose of academic and scientific research, which often includes long-term, foundational studies not immediately profitable or product-oriented.
5. **Remarks about Peregrind management**: Referring to management's statements about their workload is anecdotal and lacks context. Without more information, it's difficult to assess the truthfulness or relevance of this claim.
6. **Questioning Ms. Davis's work and implying a 'Special project'**: This part of the statement seems to insinuate that Ms. Davis's work is not legitimate or is a cover for other activities. Again, this is a serious accusation made without presenting any evidence.
Additionally, the statement potentially veers into the territory of defamation. Defamation involves making false statements about a person or entity that harm their reputation. Several elements of this statement, such as the insinuation of 'pay to play' reports, questioning the legitimacy of research, and casting doubt on the professional integrity of individuals like Ms. Davis, could be construed as defamatory if they are untrue and damaging to the reputations of those involved.
Defamation requires not only that the statements are damaging but also false. If the accusations made in the statement cannot be substantiated with evidence, and if they are proven to be false and damaging, they could potentially be considered defamatory. This is a legal consideration, and actual legal consequences would depend on specific laws and the context in which these statements were made.
In essence, the combination of unsubstantiated claims, speculative accusations, and potentially damaging insinuations without evidence makes this statement not only lacking in credibility but also possibly defamatory.”
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-a-marketing-authorization-application-has-been-submitted-to-the-uk-mhra-for-dcvax-l-for-glioblastoma-302021038.html
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
I’ll include my full post as well—the one that you were responding to when you said that no peer review was coming—I only took an excerpt before:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170370526
Flipper,
I do believe that you are correct. LC was telling us not to expect a peer review… 😶
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
Fact ✅️
LC,
Thanks for asking. Some of the patients are on social media or are featured in news stories while others are not. Jeannine Walston posted an 18-year survivor on her facebook whom I had never seen anywhere else (as one example). While Jeannine has been very visible, the other patient whom she mentioned has not put herself on social media:
Some patients advocate for access to DCVax-L by attending ASCO and other oncology conferences to support and promote the treatment.
Kat Charles, whom you highlighted earlier today, has said that others need to have access to DCVax-L and her statement seems to reflect her reason for publicizing her own story.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173532605
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173532465
https://www.uclahealth.org/news/18-year-brain-tumor-survivor-thriving-from-3rd-awake-brain-surgery-immunotherapy-vaccine-from-dr-linda-liau-at-ucla
https://www.theguardian.com/science/2022/nov/17/im-just-carrying-on-vaccine-gives-brain-cancer-patient-years-of-extra-life
ex,
Thanks for your analysis, but your reasoning is nonsensical overall. I had to consult the detector on this one 😶 …
“This statement's reasoning is weak and unreliable:
1. **Disclosure about MMTLP and Next Bridge**: The statement claims that it was well-disclosed that MMTLP holders would receive a dividend in shares of Next Bridge and that MMTLP shares would be cancelled. The reliability of this claim depends on the accuracy and clarity of the actual disclosures made by the companies involved. A citation is required.
2. **Comments on last-minute investors**: The statement criticizes those who invested in the last few days based on expectations of a short squeeze, labeling them as "fools." This is a subjective judgment and is not a statement of fact. Investment decisions can be influenced by various factors and the use of derogatory terms to describe investors is not a reasoned argument.
3. **Short position size and fails to deliver (FTD)**: The claim about the short position being small (1.2% of total shares) and the discussion on FTDs is factual in nature, but its accuracy hinges on the reliability of the data source (FINRA in this case). A data citation is required.
4. **Validity of the short squeeze theory**: The statement asserts that the idea of a distribution forcing shorts to cover is "nonsense" and often used by "BS pumpers." This is a generalization and may not hold true in all cases. The effectiveness of a short squeeze strategy can vary depending on specific market conditions and the stock in question. This part of the statement is conjecture.
5. **Outcome for late investors**: The claim that late investors received what they deserved (shares in Next Bridge) and that the value was known is again a mix of factual and subjective elements. Whether the value was "reasonably well known" is debatable and depends on the information available to investors at the time.
6. **Comment on trading halt and market operations**: The statement that a trading halt was justified due to the inability to settle trades after a certain date is a rational explanation of market mechanics. However, the tone used ("whining", "total failure to understand") is subjective and diminishes the objectivity of the argument.
In summary, the statement mixes factual information with subjective judgments and baseless generalizations. Some parts are based on data (e.g., short interest size), which lends them credibility if the data are accurate. However, the use of derogatory language and sweeping generalizations about investor behavior and market strategies undermines the overall reasoning and reliability of the statement. Biased and unsubstantiated opinions are interwoven throughout this statement rendering its argument unreliable.”
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-a-marketing-authorization-application-has-been-submitted-to-the-uk-mhra-for-dcvax-l-for-glioblastoma-302021038.html
LC,
Thanks for your posts today!!
I love you! JCI, Kat Charles, and now 15 cancers!
I agree 100%! We need to see the data and we need to see more studies getting started!
I didn’t know about the 15 cancers comment! I was hoping to see trials begin after commercialization—similar to how pembrolizumab has been in perpetual clinical trials for so many years since its original approval.
I’m going to research the “15” comment because that’s a really exciting preview of the larger trials to come!
https://www.jci.org/articles/view/169314
https://clinicaltrials.gov/study/NCT04201873
Combo is King!
Yes, 2018 .. and her diagnosis was in 2014 if I recall. We forgot about Kat Charles … thanks, LC!
https://www.dailymail.co.uk/health/article-5783403/Brain-cancer-vaccine-extend-lives-patients-years.html
https://www.telegraph.co.uk/women/life/had-cancer-treatment-could-have-saved-tessa-jowell-everyone/
LC, Our team just met with the @NorthwestBio team to learn about #DCVax and had the pleasure of speaking with longterm DCVax patients. An honor and a privilege. #endbraincancer #sno2023 pic.twitter.com/dw3X76DBru
Great post! That’s Kat Charles—she visited the NWBO booth at one of the oncology conventions. It is so beautiful when survivors make the trip and turn up at these conferences by surprise!
When Kat Charles showed up, she posted these photos on her Facebook:
https://www.bbc.com/news/health-44288503.amp
https://www.braintumourresearch.org/stories/in-hope/in-hope-stories/kat-charles
Apparently, survivors show up regularly …
J-To,
Thanks for yet another Henny Penny Chicken Little analysis, but all of your posts curiously seem like bad-faith attempts to induce panic … 🤔
NWBO does not depend on any lawsuit—the bedrock foundation of the company is the novel DCVax-L cell-based platform technology. The science and unmet medical need are the source of its value.
I had run your gem of a post through the detector 😶 …
“This statement appears to be an attempt to persuade by evoking fear. The poorly-reasoned argument is alarmist and baseless for several reasons:
1. **Speculative Assertions**: Claims like "Running out of funds" and "Huge dilution coming" are presented without evidence. Making such speculative assertions without backing them up with data or credible sources makes the statement baseless.
2. **Negative Predictions Without Basis**: Predicting "No immediate funds from the court case (maybe never)" and the need for a "Reverse Split to uplist and get institutional backing" is speculative. Legal and financial outcomes, especially in complex situations like court cases and stock listings, are uncertain and depend on numerous factors.
3. **Alarmist Tone**: The statement has an overall tone of urgency and doom, particularly in the phrase "She has backed NWBO into a very tight corner and had better do something real soon." This kind of language is designed to evoke fear and urgency rather than provide a balanced perspective or sound opinion.
4. **Lack of Context**: The statement lacks context and details that would be necessary to make a reasoned analysis of the situation. It presents a one-sided, negative view without considering other possible scenarios or interpretations.
5. **Assumption of Knowledge**: The statement assumes knowledge of the intentions and future actions of the company and its management, which is not typically available to the general public.
In summary, the statement's speculative nature, alarmist tone, and lack of substantiated facts make it unreliable and misleading as a source of information or analysis.”
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-a-marketing-authorization-application-has-been-submitted-to-the-uk-mhra-for-dcvax-l-for-glioblastoma-302021038.html
J-To,
Thanks for your analysis 😶.. but you do sound a bit like Chicken Little too 🐥
I don’t think your speculations offer much insight on the final trading day of the calendar year.
Many investors with various types of brokerage accounts have sold some of their stock holdings this week for various reasons. Required Minimum Distributions for example, and other tax-related purposes are unrelated to whichever companies someone might own shares of.
Reuters:
https://www.reuters.com/markets/us/futures-inch-up-firm-rate-cut-bets-drive-strong-gains-2023-2023-12-29/
ex,
Speaking for myself as a “long” or “soldier,” I can assert that I listen to the story presented by the regulators and the story presented by the independent peer review. I doubt that anyone “trusts” the story presented by any single individual person.
Fact ✅️
December 2023
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-a-marketing-authorization-application-has-been-submitted-to-the-uk-mhra-for-dcvax-l-for-glioblastoma-302021038.html
March 2023
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-and-advent-bioservices-announce-receipt-of-license-for-commercial-manufacturing-at-sawston-uk-facility-301776725.html
February 2022
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-commencement-of-cancer-vaccine-production-at-its-sawston-uk-facility-301484857.html
August 2022
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-approval-of-pediatric-investigation-plan-pip-by-mhra-301610850.html
July 2022
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-filing-of-application-for-license-for-commercial-manufacturing-at-sawston-uk-facility-301581737.html
December 2022
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-mhra-approval-of-license-for-gmp-manufacturing-at-sawston-uk-facility-301449083.html
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
J-TO,
Thanks for your predictions, but your post sounds extreme and a bit alarmist to me. I had to consult the detector on this one 😶 …
“This statement appears to be a weak attempt to persuade or manipulate and is unreliable for several reasons:
1. **Alarmist and Fear-Mongering Language**: Phrases like "gonna suffer a slaughter at the hands of these thieves" and "Nothing will stop them now" are designed to invoke fear and panic. This kind of alarmist language is often used to manipulate emotions rather than provide a reasoned analysis or sound opinion.
2. **Conspiracy Implication**: The claim that "They control the market" implies a conspiracy without providing evidence. Asserting market control by unspecified entities ("big bucks, always wins") is a common tactic in manipulative statements to create a sense of helplessness or inevitability.
3. **Speculative Predictions**: Predictions such as "huge dilution coming" and the stock "headed to the 50's next week" are speculative and presented without basis. Financial markets are complex and unpredictable, making such definitive predictions unreliable.
4. **Personal Opinion Presented as Fact**: The statement ends with "imo" (in my opinion), indicating that much of the preceding content is based on personal views rather than objective analysis.
5. **Negative Sentiment**: The overall tone is negative and defeatist ("HAPPY FRIGGIN NEW YEAR FELLOW BAG HOLDERS"), which can influence readers' perceptions and decisions negatively.
6. **Questionable Investment Advice**: Suggesting to "add if you got the balls to tie up your money for another 6 months to a year" is irresponsible as investment advice should be based on careful analysis, not on bravado or emotional responses to market conditions.
Overall, the statement appears to be more focused on stirring emotions and spreading negativity rather than providing a reliable, fact-based analysis or well-reasoned opinions.”
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-a-marketing-authorization-application-has-been-submitted-to-the-uk-mhra-for-dcvax-l-for-glioblastoma-302021038.html